NASDAQ : CORT
Corcept Therapeutics Incorporated — Key statistics
Healthcare · Biotechnology · United States
Last price 85.95 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 9.29B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 8.77B |
| Enterprise Value | 8.23B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 108.10M |
| Shares Outstanding | 108.10M |
| Shares Change (YoY) | -0.22% |
| Shares Change (QoQ) | +13.36% |
| Owned by Insiders (%) | 10.67% |
| Owned by Institutions (%) | 74.02% |
| Float | 96.49M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 178.81 |
| Forward PE | 21.14 |
| PS Ratio | 10.55 |
| Forward PS | 5.87 |
| PB Ratio | 12.40 |
| P/TBV Ratio | 12.42 |
| P/FCF Ratio | 82.01 |
| P/OCF Ratio | 79.94 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 151.72 |
| EV / Sales | 9.91 |
| EV / EBITDA | 1,018.52 |
| EV / EBIT | 1,285.51 |
| EV / FCF | 77.01 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.86 |
| Quick Ratio | 2.50 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.86 |
| Debt / FCF | 0.09 |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 8.23% |
| Return on Assets (ROA) | 0.47% |
| Return on Invested Capital (ROIC) | 1.79% |
| Return on Capital Employed (ROCE) | 0.87% |
| Weighted Average Cost of Capital (WACC) | 7.31% |
| Revenue Per Employee | $1.14M |
| Profits Per Employee | $74,342 |
| Employee Count | 730 |
| Asset Turnover | 0.98 |
| Inventory Turnover | 1.11 |
Taxes
| Measure | Value |
|---|
| Income Tax | -28.81M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.56 |
| 52-Week Price Change | +12.59% |
| 50-Day Moving Average | 111.98 |
| 200-Day Moving Average | 74.77 |
| Relative Strength Index (RSI) | 23.15 |
| Average Volume (20 Days) | 932,199 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 8.59M |
| Short Previous Month | 8.54M |
| Short % of Shares Out | 7.95% |
| Short % of Float | 8.90% |
| Short Ratio (days to cover) | 5.51 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 830.81M |
| Gross Profit | 816.73M |
| Operating Income | 6.41M |
| Pretax Income | 26.37M |
| Net Income | 54.27M |
| EBITDA | 8.08M |
| EBIT | 6.41M |
| Earnings Per Share (EPS) | $0.45 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 308.20M |
| Total Debt | 9.42M |
| Net Cash | 535.23M |
| Net Cash Per Share | $4.95 |
| Equity (Book Value) | 705.78M |
| Book Value Per Share | 6.54 |
| Working Capital | 285.87M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 109.70M |
| Capital Expenditures | -2.78M |
| Depreciation & Amortization | 1.68M |
| Net Borrowing | n/a |
| Free Cash Flow | 106.92M |
| FCF Per Share | $0.99 |
Margins
| Measure | Value |
|---|
| Gross Margin | 98.30% |
| Operating Margin | 0.77% |
| Pretax Margin | 3.17% |
| Profit Margin | 6.64% |
| EBITDA Margin | 0.97% |
| EBIT Margin | 0.77% |
| FCF Margin | 12.87% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 0.22% |
| Shareholder Yield | n/a |
| Earnings Yield | 0.56% |
| FCF Yield | 1.22% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $141.00 |
| Price Target Difference | 73.82% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 41.08% |
| EPS Growth Forecast (3Y) | 104.18% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 24.08 |
| Piotroski F-Score | 6 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |